Table 3.
Univariate analysis of patient survival (n = 246).
| Variable | Overall survival | |
|---|---|---|
| HR (95%CI) | P-value | |
| Age at surgery (year, ≤ 54, >54) | 6.163 (0.758–50.097) | 0.089 |
| BMI (≤ 25,>25) | 1.152 (0.288–4.611) | 0.841 |
| FIGO stage (I-II/III-IV) | 20.033 (4.04–99.343) | <0.001 |
| Tumor grade (G1-G2/G3/unknown) | 1.545 (0.673–3.547) | 0.305 |
| Histology (typeI, typeII) | 4.355 (0.878–21.603) | 0.072 |
| Lymphatic invasion (positive/negative) | 26.864(6.366–113.363) | <0.001 |
| LVSI (positive/negative) | 4.318 (0.531–35.126) | 0.171 |
| Depth of myometrial invasion (<1/2, ≥1/2) | 10.067 (2.397–42.271) | 0.002 |
| Menopause (yes, no) | 1.22 (0.292–5.107) | 0.785 |
| Combine UM (yes, no) | 1.324 (0.316–5.54) | 0.701 |
| Surgical approach (laparoscopy, laparotomy) | 1.170 (0.138–9.94) | 0.885 |
| Hypertension (yes, no) | 0.556 (0.114–2.805) | 0.486 |
| Diabetes (yes, no) | 1.771 (0.357–8.773) | 0.484 |
| Intraoperative chemotherapy(DDP)(yes, no) | 0.520 (0.104–2.609) | 0.427 |
| Postoperative chemotherapy (yes, no) | 7.222 (1.726–30.225) | 0.007 |
| Postoperative radiotherapy (yes, no) | 13.655 (3.262–57.156) | <0.001 |
| Pre-SII (>9.02 × 1011, ≤ 9.02 × 1011) | 5.681 (1.421–22.719) | 0.014 |
| Pre-NLR (>3.01, ≤ 3.01) | 4.704 (1.176–18.817) | 0.029 |
| Pre-PLR (>169.62, ≤ 169.62) | 6.329 (1.512–26.488) | 0.012 |
| CA125 (>24.58, ≤ 24.58) | 12.213 (1.501–99.395) | 0.019 |
| Pre-CRP (>3.73, ≤ 3.73) | 4.053 (1.005–16.344) | 0.049 |
| Post3-SII (>2.93 × 1012, ≤ 2.93 × 1012) | 19.589 (3.823–100.382) | <0.001 |
| Pre-MLR (>0.31, ≤ 0.31) | 6.23 (1.556–24.943) | 0.01 |
LVSI, lymphovascular space invasion; UM, myoma of uterus; SII, systemic immune-inflammation index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; CA125, cancer antigen 125; pre-, preoperative; post3-, postoperative 3 days; DDP, cisplatin.
The yellow shade highlighted that P-value less than 0.05 was statistical significance.